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1 Introduction 
 
Aerosolised medication is often prescribed for the treatment of respiratory illness such 
as asthma and chronic obstructive pulmonary disease (1, 2). The pressurised metered 
dose inhaler (pMDI) is a system designed to generate an inhalable aerosol that 
accurately delivers the active pharmaceutical ingredients (APIs) to the respiratory 
tract (3). This occurs through the following five mechanisms: impaction, 
sedimentation, interception, diffusion and electrostatic deposition (4-6). Whilst the 
first four mechanisms have been extensively studied over the years (7-9) and are 
closely related to the aerosols physical characteristics, such as particle size and shape, 
it was not until recently that electrostatics forces became an area of interest in 
pulmonary drug delivery (10).  
 
Most pharmaceutical ingredients are dielectric materials and highly susceptible to 
electrostatic charge generation and accumulation, through contact/friction charging 
between particles and material surfaces (11-13). Although it is well recognised that 
electrostatic charges can be a nuisance during manufacture and handling of 
pharmaceutical powders (by promoting agglomeration, segregation and adhesion, 
especially when fine particles are involved (14, 15), research studies using theoretical 
predictions (16-19), in vitro lung models (20, 21), in vivo animal and human subjects 
(22-26) have all suggested that electrostatic force on charged particles can 
significantly influence the aerosol performance for pulmonary drug delivery. 
 
The deposition of charged particle in the respiratory tract is described by two general 
mechanisms: space and image charge. The former space charge refers to the natural 
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repulsive force created by the electron cloud on the charged particles, especially when 
aerosol are condensed (27). Therefore, space charges play an important role during 
pMDI plume formation and consequently deposition on the pharyngeal tracheal 
region (28). The latter, image charge, predominantly influences the downstream 
aerosol deposition through induction of image charges with opposite polarity on 
nearby surfaces, for example the airway wall, hence promoting electrostatic 
deposition in the lung (10, 27).  
 
When a pMDI is actuated, the pressurised mixture of hydrofluoroalkane (HFA) 
propellant and drug (solubilised or suspended) with or without co-solvents/excipients 
is exposed to the atmospheric pressure. Consequently, the rapid transition of 
propellant into its gaseous state aerosolises the APIs carried by the HFA. Flash 
boiling, cavitation and evaporation during the atomisation process creates an 
interaction between the liquid, solid and gas components of the formulation, 
providing contact surfaces for triboelectrification. Therefore, factors that contribute to 
electrostatic charge generation for pMDI aerosols are often related to the physical and 
chemical properties of the device, including the material used for the actuator, the 
design of the orifice nozzles and chemical structure of the drug and excipients used in 
the formulation. In previous studies, different actuator materials and nozzle designs 
were selected from the triboelectric series and assessed for their influence on the 
resultant electrostatic properties (28, 29). It was found that the net charge profiles 
obtained with a formulation containing no drug and low co-solvent (ethanol 1%) 
emitted from a cone nozzle design followed the triboelectric series (29) . However, 
when an active pharmaceutical ingredient (API; beclomethasone dipropionate) was 
introduced into the formulation, no ‘trend’ was found and the net charge profiles 
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changed between different actuator materials (29). These results suggested that the 
API in a pMDI formulation has a strong influence on the overall electrostatic 
properties of the generated aerosol plume.  
 
In nature, the driving mechanism for triboelectrification is the materials’ work 
function. It is an indication of the materials’ surface property and refers to the energy 
required to remove electrons from a solid to an immediate point outside the solid (in a 
vacuum) (30). In metals, the valance band is filled with electrons up to the Fermi 
level, which overlap with the conduction band. Therefore, electron can move freely 
within a metal and the work function is the energy difference between the Fermi 
levels and the vacuum. For insulators, the Fermi level lies in the large band gap that 
exits between the valance and the conduction band, indicating that no electrons are 
present in the conduction band and it therefore has a much higher work function 
energy (31-33). During contact charging, two materials come in contact and electrons 
will transfer from lower to higher work function in attempt to reach thermodynamic 
equilibrium (34). After separation, the material that gains electron(s) will charge 
negatively and the material that loses electron(s) will charge positively. However, the 
work function is strongly influenced by the materials’ surface conditions, including 
contamination of other atoms/molecule, surface reaction (oxidation, ionisation), 
surface structures, as well as environmental factors such as humidity, especially for 
dielectric materials used in pharmaceutical aerosols (35).  
 
In pMDIs, drug particles are generated through complex phase transitions and 
chemical interactions between the propellant, co-solvent/excipients and the APIs. 
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Thus it is difficult to predict the electrostatic potential for pMDI aerosols and current 
studies can only rely on in vitro screening analysis for individual factors that could 
contribute to aerosol electrostatics. Therefore, this study focused on investigating four 
solution-based pMDIs with different APIs (beclomethasone dipropionate, budesonide, 
salbutamol base and ipratropium bromide, respectively) to elucidate how active drugs 
can influence aerosol electrostatic charge, with both insulating and conducting 
actuator materials. 
 
2 Materials and Methods 
 
2.1 Materials  
 
Five active pharmaceutical ingredients (APIs), comprising beclomethasone 
dipropionate, budesonide, flunisolide, salbutamol base and ipratropium bromide were 
chosen as model drugs (Figure 1) and supplied by Chiesi Farmaceutici S.p.A (Parma, 
Italy). Standard aluminium pMDI canisters (C128P, ID214, Batch 1002043-3, 18 ml 
brim capacity) were obtained from Presspart Manufacturing Ltd (Lancashire, UK) and 
fitted with 50 μl metering valves (ID201, batch BK0313029, Bespak Europe Ltd, 
Norfolk, UK). The propellant 1,1,1,2-Tetrafluoroethane (HFA 134a) was provided by 
Solvay Chemicals (Brussels, Belgium), and all other analytical grade chemicals, used 
as received, were purchased from Sigma-Aldrich Pty Ltd (Castle Hill, Australia). 
Water used through out the study was purified by reverse osmosis (Milli-Q, Sydney, 
Australia). 
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2.2 Sample Preparation 
 
Five solution-based pMDIs containing different API ingredients were prepared using 
pressure filling technique according to Table 1. The required quantity of individual 
drugs were accurately weighed and dissolved in co-solvent ethanol (14.9% w/w) into 
aluminum canisters. Each canister was immediately crimped with the metering valve 
and pressure filled with propellant HFA 134a using a Pamasol P2016 laboratory 
crimp and filling plant (Pamasol Willi Maäden AG, Pfaffikon, SZ). Solubility of the 
drug was confirmed visually using glass containers (Saint Gobain, France). All 
canisters were stored at ambient temperature for 24 hours prior to testing. 
 
2.3 Actuators manufacture 
 
The pMDI actuator blocks were manufactured using three different materials 
including nylon, polytetrafluoroethylene (PTFE) (both from Ensinger GmbH, 
Nufringen, Germany) and aluminum (Aalco Metals Ltd, Cobham, UK); representing 
positive, negative and conducting triboelectric materials, respectively (36). The 
nozzle design with a nominal orifice diameter of 0.3 mm and cone outer shape was 
selected to represent the most commonly utilized geometry in commercial pMDI 
actuators and manufactured with Siemens NX software using high-speed-steel cutting 
tools. Orifice diameters were confirmed using microscope and MediaCybernetics 
Image-Pro software, with dimensional accuracy up to ±0.01 mm. All actuator blocks 
were washed and sonicated with purified water and ethanol prior to first use. Air-
drying was used instead of heat drying to prevent changes to the orifice diameter. 
Adaptors to house the actuator block of the pMDI were custom designed using 
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computer aided design (ANSYS DesignModeler, release 13, ANSYS Inc, PA, USA) 
and built in acrylonitrile butadiene styrene (ABS) using a 3D printer (Dimension 
Elite, MN, USA). 
 
2.4 Measurements of aerosols electrostatic charge 
 
A modified 13 stage electrical low-pressure impactor (ELPI™, Dekati Ltd, Finland), 
without the corona charger, was used to measure the aerosol electrostatic charge 
distribution, as described previously (29, 37). The pMDI was shaken for 10 s and 
primed to waste twice using a commercial actuator before being fitted to the actuator 
block with the custom built adaptor. The airflow through the ELPI was set at 
30 L/min using Sogevac® model SV25 vacuum pump (Leybold, France) and a 
calibrated Copley® model 4000 flow meter (Nottingham, UK). The pMDI unit was 
connected to the ELPI via United States Pharmacopeia (USP) induction port and 
baseline zeroed after the electrometer readings were stabilized.  Five single actuations 
from each pMDI formulation were dispersed into the ELPI cumulatively, with 30 s 
delay between each dose. The aerosol charges were measured and current recorded 
using the ELPI-VI 4.0 software (Dekati Ltd, Finland) as femto amps per second (fA/s) 
and then converted to charge data during analysis. All experiments were randomized 
and performed in triplicate under standard laboratory conditions (temperature ~25 °C 
and relative humidity ~40–50%).  
 
2.5 High performance liquid chromatography 
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The drug captured on the actuator block, adaptor, USP induction port and impactor 
stages was recovered using rinsing solution (Table 2) specific for each API and 
quantified chemically using a Shimadzu prominence UFLC system equipped with a 
SPD-20A UV-vis detector, LC-20AT solvent delivery unit, SIL-20A HT autosampler 
(Shimadzu Corporation, Japan). Chromatographic conditions for each API 
formulation are summarized in Table 2. Fresh drug standards were prepared in rinsing 
solution and all mobile phase solutions were filtered through 0.45 μm filters and 
degassed by ultra-sonication for 10 min. The HPLC method was validated for all 
APIs throughout the concentration range of 0.1-100 μg/mL. 
 
2.6 Data Analysis 
 
Aerosol electrostatic charge data for each pMDI formulation were derived from 
electric current results obtained from the ELPI. The net charge was calculated as the 
total charge from the 13 stages of the impactor and shown as the mean for the three 
experiments. The mass recoveries of individual APIs were analyzed as the total mass 
of five cumulative actuations. Total ex-valve dose, throat USP deposition and fine 
particle fraction (<6.66 μm) were calculated and expressed as a percentage of the 
targeted dose (5 accumulative shot of 50 μg per shot, equivalent to 250 μg).  Mass 
median aerodynamic diameter (MMAD) was calculated assuming linearity between 
84-16% of the cumulative mass undersize lognormal distribution and the geometric 
standard deviation (GSD) was determined as (d0.84/d0.16)1/2. Charge to mass ratio was 
analysed as total charge and mass of three replicate experiments. Two sample Student 
t-test (heteroscedastic) and one-way ANOVA (unstacked) analysis was performed 
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using STATPlus® statistics software package (AnalystSoft Inc, VA, USA). 
Significant difference was based p<0.05. 
3 Results and Discussion 
 
The influence of different active pharmaceutical ingredients, formulated as solution 
pMDIs, on the aerosol performance and electrostatic charge profiles have been 
investigated in this study and results are discussed below.  
 
3.1 The effect of APIs on overall aerosol net charge using different actuator materials 
 
The net charge of five different APIs and three different actuator materials were 
calculated as the total charge derived from the 13 stages of the ELPI. The mean of the 
three replicate experiments are shown in Figure 2. Actuator material Nylon and PTFE 
were selected to represents the extreme of the triboelectric series, with Nylon being 
positive and PTFE negative charged materials, respectively. Aluminium is ranked 
close to neutral and was selected as conducting material for comparison (38).  
 
In general, all three actuator materials showed the same net charge trend across the 
five active drug ingredients, with beclomethasone dipropionate (BDP), budesonide 
(BUD) and flunisolide (FS) showing positive net charges, while salbutamol base (SB) 
and ipratropium bromide (IPBr) having negative net charges. Statistical analyses 
using one-way ANOVA showed no significant differences between nylon, aluminium 
and PTFE actuators, when the same API was used, but significant difference across 
different APIs when the same actuators was used (one way ANOVA, p<0.05). This is 
 10 
consistent with a previous study where the addition of active drug ingredient in a 
pMDI formulation diminished the actuator materials’ triboelectric effect on aerosol 
charges (39).   
 
For both Nylon and PTFE actuators, which are insulating thermoplastics with 
distinctively different static charging trends, BDP, BUD and FS showed positive 
charges, ranging from 134.78 ± 127.29 pC (BUD with Nylon actuator) to 332.74 ± 
86.74 pC (BUD with PTFE actuator), but no significant differences (Student t test, 
Figure 2). These results suggest that the API may have a dominant effect on the 
measured aerosol electrostatic charge (Figure 2). BDP, BUD and FS are all 
corticosteroids with very similar molecular structures (Figure 1). They all contain 
electronegative atoms, such as oxygen and fluorine, capable of dipole-dipole 
attraction and hydrogen bonding. The interaction between the corticosteroids, HFA 
134a and co-solvent ethanol could result in a change of work function for the final 
aerosol particles, and similar functional groups on the BDP, BUD and FS molecules 
could produce comparable work functions for the three drugs, inducing similar 
contact charging profiles with the actuator material surfaces. Additionally, it is 
important to recognize that triboelectrification between insulators are complex. In 
theory, electrons would flow from a material with low work function to the one with 
higher work function. From the net charge results, BDP, BUD and FS all have 
dominantly positive charge polarity, indicating an electron transfer from the aerosol to 
the actuator material (Figure 2, Nylon and PTFE). A possible explanation for such 
observation could be the presence in the formulation of 15% co-solvent ethanol. A 
previous study has shown that ethanol reduced the electronegativity of HFA 134 
propellant and shifted the net charge for a pMDI aerosol toward positive/neutrality 
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(39). At the same time, interaction between co-solvent, drug and propellant within the 
formulation could potentially reduce the dielectric properties of the aerosol, hence 
reducing the work function energy. Lower work function allows the material to lose 
electrons, which is reflected in the net charge results (Figure 2).  
 
When BDP, BUD and FS pMDI formulations were used with the aluminum 
conducting metal actuator, results showed almost neutral net charge profiles, with 
significantly lower magnitude compared with nylon and PTFE, with an average less 
than 50 pC (Figure 2, Aluminum). These results might be due to the fact that the work 
function of these corticosteroids formulations are close to the work function of 
aluminum, hence electron transfer between the aerosols and material surface is 
limited. Meanwhile, the conducting property of aluminum allows free movement of 
electrons within the solid body, hence could form a negative electron cloud on the 
surface of the material and potentially neutralize the positive charges on the aerosol 
particles after contact charging.  
 
In comparison, significant differences in net charges were observed between SB and 
IPBr (Figure 2) with the same actuator material (Student t-test, p < 0.05). SB showed 
a negative charge profile for all three actuators, with the highest magnitude shown 
with PTFE at ‒930.32  ± 300.25 pC (Figure 2). SB is a short acting β2-adrenergic 
receptor agonist. Its molecular structure contains three hydroxyl groups. It is 
hypothesized that the strong electronegativity of the HFA 134a propellant may attract 
hydrogen ions forcing the hydroxyl groups to become hydroxide anions and carry 
negative charges. Therefore, the overall net charge for SB is negative (Figure 2).  
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IPBr also demonstrated negative charge polarity with all actuator materials tested, but 
with a smaller magnitude, at an average of ‒334.52 ± 90.73 pC. IPBr is an 
anticholinergic drug, with a permanently positively charged ammonium cation and 
negatively charged bromide ion. The bipolar nature of IPBr could cause potential 
neutralization of the electrostatic charges generated following triboelectrification of 
the aerosol droplets with the actuator materials, hence generating a reduced net charge 
magnitude (Figure 2). 
 
In is interesting to note that the conducting actuator aluminum did not show 
significant difference in net charges with SB and IPBr, compared with nylon and 
PTFE actuators. Probably, due to the functional groups and ions present, the 
conductivity of SB and IPBr increases and the work function can be reduced. This 
should cause electrons to flow from the aerosols to the material surfaces, in contrast 
with the observed results (Figure 2). These results could be related to the presence of 
ionic groups within the formulation, depended on the pH of the HFA/ethanol solution. 
However, since PMDIs are pressurised systems, it is difficult to determine the actual 
physiochemical properties of the mixture inside the canisters and therefore hard to 
predict the possible downstream effects of molecular functional groups on aerosol 
electrostatics.  Future studies will investigate this aspect of the project. 
 
3.2 The effect of APIs on aerosol performance using different actuator materials 
 
Aerosol electrostatic results have shown that the APIs have a dominant effect on 
pMDI aerosol charge profiles. Since aerosol performance can be influence by both 
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drug formulations and device design, it is important to investigate the aerodynamic 
properties for the pMDIs and examine the correlation between particle characteristics 
and static charges. 
 
Cumulative particle size distribution plots were calculated from the cumulative mass 
under-size for each individual API and are shown in Figure 3.  Statistical analyses 
using one-way ANOVA showed no significant differences between drugs for the 
same material, as well as the same drug with different materials, indicating different 
drug ingredients have no influence on particle size distribution for the pMDI 
formulations. Significant differences in MMADs were observed across the different 
APIs for all three actuator materials (one way ANOVA); with BDP 0.76 ± 0.01 μm, 
BUD 0.91 ± 0.07 μm, FS 0.89 ± 0.00 μm, SB 0.70 ± 0.02 μm and IPBr 0.95 ± 0.02 
μm, respectively. A general mean GSD value at 2.31 ± 0.29 μm indicated all pMDI 
formulations were poly-dispersed. 
 
Furthermore, total ex-valve dose, throat USP deposition and fine particle fractions 
less than 6.66 μm were analyzed, based on the percentage of the designed target dose 
and shown in Figures 4, 5 and 6.  Statistical analyses indicated significant differences 
in total ex-valve dose between different APIs using nylon, aluminum and PTFE 
actuators. Higher emitted dose were shown with BDP and FS for all three materials, 
compared with the other three APIs (Figure 4), suggesting less drug retention in the 
device. However, the emitted dose for all drugs did not correlate with the static charge 
profiles, which could be due to reduced charge magnitude (Figure 2). 
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Drugs collected in the USP throat for all API formulations are shown in Figure 5. 
One-way ANOVA showed statistically significant difference across different APIs for 
the same actuator material; SB had the smallest USP deposition comparedwith the 
other drugs. This is an interesting observation, as SB had the most negative net charge 
profile. It was hypothesized that unipolar dominant charged aerosols, where plume 
expansion is possible due to the presence of space charges, could have increased the 
deposition to the throat region, but this was not reflected in the SB results. A possible 
explanation could be linked to the density of the aerosol droplets. From the molecule 
structure of SB (Figure 1), it is know that SB had the lowest density among the five 
APIs studied. This generates smaller particles after atomization, supported by the 
small MMAD of SB (0.70 ± 0.02 μm). Although small size particles tends to charge 
more negatively (40), it could also travel at a higher velocity, limiting the time for the 
plume expansion effects due to space charge, reducing throat deposition (Figure 5). 
 
The fine particle fraction of particles less than 6.66 µm was calculated based on the 
drug mass recovered from the ELPI impactor stages and is shown as a percentage of 
the target dose in Figure 6. This is a representation of the respiratory fraction of the 
pMDI formulation that is suitable for lung deposition. No significant differences were 
found in FPF for the same drug with different actuator materials. However, significant 
higher fine particle fractions were found with BDP using nylon (36.55% ± 5.91) and 
PTFE (34.34% ± 7.09) actuators, respectively, compared with aluminum and other 
pMDI formulations.  
 
Although these results show that larger amount of positive charge particles could 
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result in a higher fine particle fraction, the same results were not observed with other 
APIs and actuator materials (Figure 6). In general, there was no clear relationship 
between the electrostatic charges and aerosol performance, using different APIs. 
 
3.3 The effect of APIs on charge to mass ratio using the aluminum actuator material 
 
It is important to note that while there is no clear trend between aerosols charge and 
aerosol performance, the elementary charge of each particle can be important in 
understanding the involvement of charges in particle behaviours. To investigate this 
aspect, mass to charge ratios were calculated by dividing the net charge with the total 
mass recovery from the impactor. Results are shown in Table 3.  
 
Similar trends as the net charge have been observed with the charge to mass ratio. 
Corticosteroids BDP, BUD and FS had positive elementary charges, with small 
magnitudes, ranging from 0.65 ± 0.30 pC/μg (BUD with aluminium) to 29.21 ± 8.78 
pC/μg (BUD with PTFE) (Table 3), respectively. SB particles carried the most 
negative charges, especially with PTFE actuator (‒94.57 ± 30.45 pC/μg), which is 
equivalent to an elementary charge of ‒31.04 ± 12.59 pC per particle. This amount of 
charge per particle is the highest among all five APIs studied, but is low compared 
with previous studies. Melandri et al. has shown that mono-dispersed particles could 
increase deposition when particles carried about 200 elementary charges per particle 
(22, 41); where Yu and Chandra found a threshold of 50 elementary charge per 
particle was required to alter deposition of 1 μm particles (17). Both these studies 
have demonstrated deposition changes with unipolar charges and mono-dispersed 
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particles. However, the dielectric properties of inhalation pharmaceutical powder 
show the aerosol will be dominated by bipolar charges, and the GSD value obtained 
from this study also shows particles are poly-dispersed. Therefore, no clear trends 
were observed between aerosol electrostatics and aerosol depositions for different 
APIs. However, it is significant that the use of drug ingredients in pMDI formulation 
is the determinant in aerosol charge polarity.  
 
4 Conclusions 
 
The API present in a pMDI has a dominant effect on the electrostatic properties of the 
formulation, overcoming the charge effect arising from the actuator materials. The 
presence of ionic functional groups in a drug molecule structure significantly 
influences the polarity of the generated electrostatic charges. In this study, no specific 
trend was observed between the deposition patterns and aerosol electrostatic charge 
profiles for the five API pMDIs formulations. However, results have shown that the 
electrostatic charges for a solution-based pMDI could be related to the interactions of 
the chemical ingredients and change in the work function for the overall formulation.  
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6 Tables and Figures 
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Table 1: Formulation details for the solution based pMDIs with different APIs.  
APIs Target Dose (μg) Drug (% w/w) Ethanol (% w/w) HFA 134a (% w/w) 
BDP 50 0.1 14.9 85 
BUD 50 0.1 14.9 85 
FS 50 0.1 14.9 85 
SB 50 0.1 14.9 85 
IPBr 50 0.1 14.9 85 
BDP: Beclomethasone Dipropionate; BUD: Budesonide; FS: Flunisolide; SB: Salbutamol Base; IPBr: Ipratropium Bromide 
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Table 2: Chromatographic conditions for the chemical assay.  
Formulations Rising solution Mobile Phase (v/v) Column  
 Flow Rate 
(ml/min) 
Injection 
Volume 
(μl) 
UV 
Detection 
BDP 80% Methanol 68 % Methanol  Waters 
Novapak® 
C18 
1 100 240nm 
  20% H2O 32 % 0.05% w/v Ammonia Acetate aqueous solution  
BUD 80% Methanol 60% Methanol  Waters 
Novapak® 
C18 
1 100 243nm 
  20% H2O 40% deionized water 
FS 80% Ethanol 35% Acetonitrile Waters 
Bondapak® 
C18 
2 50 254nm 
  20% H2O 65% 1% v/v acetic acid solution 
SB 80% Methanol 60% Methanol  Waters 
Novapak® 
C18 
1.5 100 276nm 
  20% H2O 40% 0.1 w/v SDS aqueous solution 
IPBr 100% H2O 20% Acetonitrile  Waters 
Novapak® 
C18 
1 100 210nm 
    80% Sodium phosphate Buffer pH4 
BDP: Beclomethasone Dipropionate; BUD: Budesonide; FS: Flunisolide; SB: Salbutamol Base; IPBr: Ipratropium Bromide 
All mobile phases were filtrated through a 0.45 μm filter prior to HPLC use 
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Table 3: Total charge per mass (pC/μg) of the APIs, (n=3, ±SD) 
API Nylon (pC/μg ± SD) Aluminium (pC/μg ± SD) PTFE (pC/μg ± SD) 
BDP 11.63 ± 3.37 3.05 ± 1.69 18.48 ± 17.09 
BUD 11.10 ± 10.58 0.65 ± 0.30 29.21 ± 8.78 
FS 18.19 ±5.98 0.81 ± 0.83 21.55 ± 3.89 
SB −73.63 ± 25.28 −35.46 ± 7.54 −94.57 ± 30.45 
IPBr −38.23 ± 6.24 −26.23 ± 6.20 −28.38 ± 25.05 
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Figure 1: Molecule structure for the five selected active pharmaceutical 
ingredients. 
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Figure 2: Net charge for all APIs with nylon, aluminium and PTFE actuators, 
(n=3 ±SD) 
 25 
 
 
Figure 3: Cumulative mass undersize plots for all APIs with nylon, aluminium 
and PTFE actuators (n=3, % CMU ±SD) 
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Figure 4: Total ex-valve dose for all APIs with nylon, aluminium and PTFE 
actuators, expressed as % of targeted dose: 5 accumulative shots of 50 μg per 
shot equivalent to 250 μg,  (n=3 ±SD) 
 
 
 
 
Figure 5: Throat USP deposition for all APIs with nylon, aluminium and PTFE 
actuators, expressed as % of targeted dose: 5 accumulative shots of 50 μg per 
shot equivalent to 250 μg,  (n=3 ±SD) 
 
 
 27 
 
Figure 6: Fine particle fraction less than 6.66 μm for all APIs with nylon, 
aluminium and PTFE actuators, expressed as % of targeted dose: 5 
accumulative shots of 50 μg per shot equivalent to 250 μg,  (n=3 ±SD) 
 
 
 
 
 
 
 
 
 
 
